

Eisai Co., Ltd. 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 , Japan
Phone: 03- 3817-5120 Fax: 03- 3811-3077

Eisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their families to enhance the quality of life.

FOR IMMEDIATE RELEASE

No. 07-46

November 29, 2007

Eisai Co., Ltd.

Eisai Submits NDA Application of KES524 for Obesity Management in Japan

Design of Phase III Double-Blind Comparative Study and the Results in Japan

1. Design

Subject: 342 obese patients (171 patients/arm)

Major Inclusion Criteria:

- ☒ BMI ≥ 25 Kg/m², VFA (Visceral Fat Area) ≥ 100 cm²
- ☒ Diagnosed type 2 diabetes, 6.1% \leq HbA_{1c} (Hemoglobin A1c) $< 9.0\%$
- ☒ Dyslipidemia TG ≥ 150 mg/dL and/or HDL-C < 40 mg/dL

Duration: 4-week screening, 52-week treatment, and 12-week following up

Administration: KES524 (10 mg/day or increased to 15 mg/day if response was inadequate) or placebo

Primary Endpoints: Change in bodyweight (